Paclitaxel Injection

This product is a new type of anti-microtubule drug that promotes tubulin polymerization, inhibits depolymerization, maintains tubulin stability, and inhibits cell mitosis. In vitro experiments have shown that paclitaxel has a significant radiosensitization effect, which may be to stop cells in the G2 and M phases that are sensitive to radiotherapy.

1. Main ingredients: Paclitaxel Chemical name: (2S, 5R, 7S, 10R, 13S) 10, 20 bis (acetyloxy) 2-benzoyloxy 1, 7-dihydroxy 9-oxo-5, 20-epoxytaxane 11-ene 13-yl (3S) benzamido 3-phenyl D lactate. Chemical structure: Molecular formula: C47H51NO14 Molecular weight: 853.92 2. Excipients: polyoxyethylated castor oil, anhydrous ethanol, anhydrous citric acid.

This product is a colorless to light yellow clear viscous liquid.

First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.

To prevent allergic reactions, 20 mg of dexamethasone should be taken orally 12 hours and 6 hours before paclitaxel treatment, 50 mg of diphenhydramine should be given intramuscularly or orally 30 minutes to 60 minutes before treatment, and 300 mg of cimetidine or 50 mg of ranitidine should be given intravenously. The single-drug dose is 135-200 mg/m2, and with the support of granulocyte colony-stimulating factor (G-CSF), the dose can reach 250 mg/m2. Dilute paclitaxel with saline, 5% glucose or 5% glucose saline to a solution of 0.3-1.2 mg/ml and drip it intravenously for 3 hours. The combined dose is 135-175 mg/m2, repeated every 3-4 weeks.

Allergic reactions: The incidence is 39%, of which severe allergic reactions occur in 2%. Most are type I allergic reactions, manifested as bronchospasm, dyspnea, urticaria and hypotension. Almost all reactions occur in the first 10 minutes after medication. Myelosuppression: It is the main dose-limiting toxicity, manifested as neutropenia, thrombocytopenia is rare, and generally occurs 8-10 days after medication. The incidence of severe neutrophils is 47%, and the incidence of severe thrombocytopenia is 5%. Anemia is more common. Neurotoxicity: The incidence of peripheral neuropathy is 62%, the most common manifestations are mild numbness and paresthesia, and the incidence of severe neurotoxicity is 6%. Cardiovascular toxicity: There may be hypotension and asymptomatic short-term bradycardia. Muscle and joint pain: The incidence is 55%, occurring in the joints of the limbs, and the incidence and severity are dose-dependent. Gastrointestinal reactions: The incidences of nausea, vomiting, diarrhea and mucositis are 59%, 43% and 39% respectively, generally mild and moderate. Hepatotoxicity: ALT, AST and AKP increase. Hair loss: The incidence is 80%. Local reactions: Intravenous infusion of drugs and drug extravasation can cause local inflammation.

People who are allergic to polyoxyethyl castor oil. People whose neutrophil count is less than 1500/mm3 are contraindicated.

Precautions for children: Precautions for pregnancy and lactation: Paclitaxel has been shown to affect embryonic growth in animal experiments, so it is contraindicated for pregnant women. Women of childbearing age should not become pregnant during treatment. Precautions for the elderly:

Since quinupristin/dalfopristin is a cytochrome P450-3A4 enzyme inhibitor, simultaneous administration can increase the blood concentration of this drug. When used in combination with telazoma, the serum trough concentration level of telazoma increases by about 1.5 times. Clinical trials have shown that the combination of the two has a better effect. Cisplatin can reduce the clearance rate of this drug by about 1/3. If this drug is given after cisplatin, it can produce more severe bone marrow suppression. When used in combination with doxorubicin, studies have shown that continuous infusion of this drug for 24 hours and then continuous infusion of doxorubicin for 48 hours can significantly reduce the granulocytopenia and stomatitis of doxorubicin. Giving epirubicin immediately after using this drug can aggravate the toxicity of this drug. Ketoconazole can inhibit the metabolism of this drug. Fosphenytoin and phenytoin can reduce the effect of this drug by inducing cytochrome P450. Vaccination with live vaccines (such as rotavirus vaccine) when using this drug can increase the risk of infection with live vaccines. Foreign data recommend that leukemia patients in remission should not be used when using this drug, and live vaccines can be vaccinated at least three months after the end of chemotherapy.

Keep in a dark and airtight container below 25℃.

5ml:30mg

24 months

Shijiazhuang Kaida Bioengineering Co., Ltd.

• Founded in:

  1991-09-17

• Address:

  No. 198, Xiangjiang Road, Shijiazhuang High-tech Zone

• Tax NO.:

  91130101104435383N

• Registered Funds:

  3 million yuan

• Website:

  Log in to view

• Email:

  Log in to view